证券代码：001380 证券简称：华纬科技 公告编号：2025-052 华纬科技股份有限公司 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、对外投资暨关联交易概述 华纬科技股份有限公司（以下简称"公司"）于2025年1月24日召开第三届董 事会第十九次会议审议通过了《关于拟投资设立合资公司暨关联交易的议案》， 同意公司通过全资孙公司金晟實業投資有限公司、全资孙公司JINSHENG USA LLC与浙江万安科技股份有限公司（以下简称"万安科技"）全资孙公司萬安科 技（香港）北美投資有限公司共同投资设立合资公司建设墨西哥生产基地，投资 总额不超过3,000万美元（其中公司通过全资孙公司金晟實業投資有限公司、全资 孙公司JINSHENG USA LL出资不超过1,950万美元，合计占股65%，万安科技通过 全资孙公司萬安科技（香港）北美投資有限公司出资不超过1,050万美元，合计占 股 35% ） 。 具 体 情 况 详 见 公 司 于 2025 年 1 月 25 日 在 巨 潮 资 讯 网 （http://www.cninfo.com.cn）披露的《关于拟投 ...

报告撰写人、德国联邦外贸与投资署专家托马斯·博扬表示，中国继续位居德国投资主要来源国前列， 德国也是中国在欧洲投资布局的最大受益方。他指出，中企越来越聚焦可再生能源、电池供应链、汽 车、医疗技术、机器人等领域，尤其是这些行业的软件解决方案。博扬还说，除德国外，中企对外投资 活动在全球范围内同样保持强劲增长势头，尤其在新冠疫情结束后增幅显著。 中国德国商会本月早些时候发布报告称，尽管面对高额关税威胁，德企对华投资战略保持强劲。50%的 企业计划未来两年增加投资，另有超1/3的受访企业加速在华本土化以应对贸易紧张局势。德国 table.media网站3月报道称，2024年，德国企业在中国新投资了57亿欧元，与上一年相比增长了1/4。 【环球时报特约记者 文简】德国联邦外贸与投资署12日发布的《2024年外国企业在德投资报告》显 示，中国是德国第三大投资来源国，项目数量达199个。 报告显示，2024年，德国各州共登记1724个外国直接投资项目，包括绿地投资、扩建项目、迁移项目， 但不包括并购，同比小幅下降2%；外国企业在德投资金额仍保持在232亿欧元的高位，1/5的外企将德 国作为生产或研发基地。美国是德国最大的 ...

Group 1 - The company has changed its accounting policies in accordance with the latest regulations issued by the Ministry of Finance, effective from January 1, 2024 [1][3][4] - The new accounting policies include the "Interim Regulations on Accounting Treatment Related to Enterprise Data Resources" and "Interpretation No. 18 of the Enterprise Accounting Standards," which provide guidelines for accounting treatment of data resources and quality guarantees [4][6] - The audit committee and board of directors have approved the changes, stating that they will provide more reliable accounting information and better reflect the company's financial status [6][7][8] Group 2 - The company plans to improve its asset structure and optimize resource allocation by investing in its subsidiary, Hubei Haili Meida Automobile Co., Ltd., which has been experiencing continuous losses [24][54] - The investment will involve forming new partnerships with Beijing Zhike Industrial Investment Holding Group Co., Ltd., with the company contributing its equity in Hubei Haili Meida [24][25] - The transaction is expected to enhance the operational status of Hubei Haili Meida and will not significantly impact the company's current financial condition or operating results [54][55] Group 3 - The company has appointed Xinyong Zhonghe Accounting Firm as its auditor for the 2025 fiscal year, pending approval from the shareholders' meeting [10][18] - Xinyong Zhonghe has a strong track record, with significant revenue from audit services and a large number of registered accountants [11][12] - The audit fees for the current period are set at 2.12 million yuan, which is a decrease from the previous year [16]

Fundraising Overview - The company raised a total of RMB 435,416,006.56 through the issuance of 38,261,512 shares at a price of RMB 11.38 per share, with net proceeds after fees amounting to RMB 396,359,402.79 [1][2] - The actual usable funds after deducting underwriting and other issuance costs were RMB 378,305,888.60 [2] Fund Usage and Management - As of December 31, 2024, all fundraising projects have been completed, and any surplus funds were permanently allocated to supplement working capital [3][6] - The company adhered to regulatory requirements for managing and using the raised funds, with no violations reported [4][13] - The company established a tripartite supervision agreement with its underwriter and banks to ensure proper management of the funds [4] Fund Allocation and Surplus - The company used RMB 459.73 million of the excess funds to permanently supplement working capital, which is within the limit of 30% of the total excess funds [8][11] - By the end of 2024, all excess funds totaling RMB 2,867.20 million were permanently allocated to working capital [9] Financial Performance - The company reported a net profit of RMB 51,336,898.36 for the year 2024, with a proposed cash dividend of RMB 5.00 per 10 shares, totaling RMB 77,066,773.50 [20][21] - The total cash distribution and share buyback amounted to RMB 112,509,858.26, representing 219.16% of the net profit [21] Audit and Compliance - The company’s fundraising and usage report was verified by the accounting firm, which confirmed compliance with relevant regulations [14][15] - The company plans to continue its relationship with the auditing firm, Lixin, for the 2025 fiscal year [28][29] Stock Incentive Plan - The company adjusted the grant price for its 2023 stock incentive plan to RMB 7.88 per share following a cash dividend distribution [57][59]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600774 股票简称：汉商集团 编号：2025-017 汉商集团股份有限公司 关于对外投资暨关联交易的公告 本公司及董事会全体成员保证公告内容不存在虚假记载、误导性陈述或者重大遗漏，并对其内容的真 实、准确和完整承担法律责任。 重要内容提示： ● 交易事项：汉商集团股份有限公司（以下简称"公司"或"汉商集团"）拟与武汉荣辰维诺投资有限公司 （以下简称"荣辰维诺"）、阳新农业发展集团有限公司（简称"阳新农发"）共同出资设立武汉云上创新 发展合伙企业（有限合伙）（暂定名，以市场监管部门登记的名称为准，以下简称"合伙企业"），合伙 人总认缴出资额为25,000万元，其中公司以货币出资3,000万元，占合伙企业总认缴出资额的12%。 ● 至本次关联交易为止，过去12个月内，公司与同一关联人或不同关联人之间类别相关的关联交易次数 为2次，交易金额为6,000万元，未超过公司最近一期经审计净资产绝对值5％以上。 ● 本次交易不构成重大资产重组，无需获得公司股东大会的批准。 ● 风险提示：1、本次设立合伙企业尚需工商注册登记等有关审批机关的批准和核准，尚具有不确 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：600252 证券简称：中恒集团 公告编号：临2025-42 广西梧州中恒集团股份有限公司 关于控股子公司莱美药业参与投资广东东纳协同产业投资合伙企业（有限合伙）的进展公告 具体内容详见公司分别于2025年3月6日、2025年4月4日在上海证券交易所网站（www.sse.com.cn）披露 的《广西梧州中恒集团股份有限公司关于控股子公司莱美药业参与投资广东东纳协同产业投资合伙企业 （有限合伙）的公告》（公告编号：临2025-22）、《广西梧州中恒集团股份有限公司关于控股子公司 莱美药业参与投资广东东纳协同产业投资合伙企业（有限合伙）的进展公告》（公告编号：临2025- 37）。 二、对外投资进展情况 2025年4月17日，公司控股子公司莱美药业收到东纳医疗基金管理人广东东纳私募基金管理有限公司关 于东纳医疗基金资金募集进展事项的通知，东纳协同已向东纳医疗基金实缴出资8,100万元，东纳医疗 基金的资金募集已按约完成。截至本公告披露日，各合伙人认缴出资额和实缴出资额的情况具体如下： 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 ...

Group 1 - The board of directors of Jiaze New Energy Co., Ltd. held its 38th meeting on March 24, 2025, with 8 out of 9 directors present, and the meeting complied with legal and regulatory requirements [1][2] - The board approved the 2024 annual work report and the general manager's work report, both receiving unanimous support [1][2] - The financial settlement report for 2024 was approved, showing a net profit attributable to shareholders of 630,123,882.82 yuan, while the parent company reported a net loss of 55,672,643.66 yuan [2][3] Group 2 - The profit distribution plan for 2024 includes a cash dividend of 243,435,218.20 yuan, which is 38.63% of the net profit attributable to shareholders, with total cash dividends for the year amounting to 267,778,730.54 yuan [2][3] - The company will not conduct a capital reserve transfer to increase share capital for 2024 [3] - The board agreed to recognize credit impairment losses and set aside a provision of 1,808,482.85 yuan for expected credit losses based on financial asset evaluations [4][5] Group 3 - The board approved the 2024 annual report and the internal control self-assessment report, both to be submitted for shareholder approval [6][7] - The board also approved the 2025 operational plan and financial budget, with unanimous support [7][8] - The board agreed to adjust the chairman's investment and financing decision-making authority for 2025, increasing the limits for external investments and financing [8][9] Group 4 - The company plans to apply for a credit limit from financial institutions for 2025 to support its operational needs [9][10] - The board approved providing guarantees for financing loans and infrastructure projects, with specific conditions outlined for collateral [10][11] - The company intends to establish a joint venture with Guangxi Energy Group to develop wind power projects, with plans for 10 projects totaling approximately 1.4 million kilowatts [11][12] Group 5 - The board approved investments in wind power projects totaling approximately 264,992.83 million yuan and a shared energy storage project estimated at 41,052.08 million yuan [12][13] - The company will increase capital for its subsidiaries to support wind power project construction, with specific amounts detailed for each subsidiary [14][15] - The board agreed to initiate preliminary work for a pumped storage power station project [15]

步长制药: 山东步长制药股份有限公司关于控股子 公司拟对外投资设立子公司的进展公告 证券代码：603858 证券简称：步长制药 公告编号：2025-056 山东步长制药股份有限公司 关于控股子公司拟对外投资设立子公司的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、对外投资概述 根据山东步长制药股份有限公司（以下简称"公司"或"步长制药"）总体 发展规划，为促进公司控股子公司上海合璞医疗科技有限公司（以下简称"上海 合璞医疗科技"）的经营发展，上海合璞医疗科技拟与苏州工业园区明普医疗科 技有限公司（以下简称"明普医疗"）共同投资设立新公司苏州合璞医疗器械有 限公司（暂定名，最终名称以工商部门核准登记为准）（以下简称"苏州合璞医 疗器械"）。苏州合璞医疗器械注册资本 200 万元,上海合璞医疗科技出资 140 万 元，持股比例 70%,明普医疗出资 60 万元，持股比例 30%。本次投资完成后，苏 州合璞医疗器械将会纳入公司合并报表范围。具体内容详见公司 2025 年 3 月 外投资设立子公司的公告》（公告编号：2 ...

德业股份: 关于公司与专业机构共同投资设立投资 基金的进展公告 为推动公司持续发展，充分利用专业机构的经验和资源，拓宽公司产业布局 和战略视野，宁波德业科技股份有限公司（以下简称"公司"）与宁波曦晨私募 基金管理有限公司、戴志勇共同投资设立宁波德润泰和创业投资合伙企业（有限 （以下简称"投资基金"、"德润泰和"）。投资基金认缴出资总额为 10,000 合伙） 万元，公司作为有限合伙人以自有资金认缴出资人民币 8,800 万元，出资占比 戴志勇认缴出资人民币 1,000 万元，出资占比 10%。具体内容详见公司 2025 年 构共同投资设立投资基金的公告》（公告编号：2025-008）。 二、投资基金进展 近日，公司收到宁波曦晨私募基金管理有限公司通知，投资基金已完成工商 登记手续，取得宁波市北仑区市场监督管理局核发的营业执照，具体信息如下： 管部门批准不得从事吸收存款、融资担保、代客理财、向社会公众集（融）资等 金融业务）（除依法须经批准的项目外，凭营业执照依法自主开展经营活动）。 特此公告。 证券代码：605117 证券简称：德业股份 公告编号：2025-009 宁波德业科技股份有限公司 关于公司与专业机构 ...